TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics Provides Corporate Update and 2024 Outlook

08 Jan 2024 06:00:01 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

14 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS

04 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

21 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Third Quarter 2023 Financial Results

07 Nov 2023 15:01:01 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

03 Nov 2023 09:46:45 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Third Quarter 2023 Financial Results

24 Oct 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

13 Oct 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Oct 2023 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

26 Sep 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

21 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Sep 2023 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

05 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference

31 Aug 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

24 Aug 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Second Quarter 2023 Financial Results

03 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Second Quarter 2023 Financial Results

20 Jul 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals

17 Jul 2023 07:00:00 By Nasdaq GlobeNewswire